Cover Image
市場調查報告書

(5EU)的醫藥品市場預測與分析季節性流感疫苗:歐洲主要5個國家

Seasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 427226
出版日期 內容資訊 英文 290 Pages
訂單完成後即時交付
價格
Back to Top
(5EU)的醫藥品市場預測與分析季節性流感疫苗:歐洲主要5個國家 Seasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025
出版日期: 2016年11月01日 內容資訊: 英文 290 Pages
簡介

本報告提供歐洲主要5個國家 (5EU:法國、德國、義大利、西班牙、英國) 的季節性流感疫苗臨床實驗趨勢與上市預測相關分析,季節性流感概要和症狀、原因,目前的主要治療方法,現在臨床實驗中的開發中產品的概要 (功效,SWOT分析等),市場規模預測 (總計11年份),主要的推動市場要素與其影響度等相關的調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 症狀、預後

第4章 疾病管理

  • 季節性流感的疫苗接種政策
    • 疫苗接種相關建議,與最常給藥的疫苗
  • 法國
    • 流感疫苗接種相關建議、政策
    • 臨床診療
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭產品的評估

  • 概要
  • 產品簡介:領導品牌藥,不活化疫苗
    • Fluzone Quadrivalent
    • Fluzone High-Dose
    • Fluzone Intradermal
    • Vaxigrip
    • Fluarix Tetra
    • Fluvirin
    • Afluria
    • Agrippal
  • 產品簡介:領導品牌藥,不活化疫苗 (輔助劑)
    • Fluad
  • 產品簡介:領導品牌藥,減毒活病毒疫苗
    • FluMist Quadrivalent
  • 產品簡介:領導品牌藥,細胞培養疫苗
    • Flublok
    • Flucelvax
  • 其他季節性流感疫苗
    • Influvac
    • 小型的品牌藥

第6章 未滿足需求與市場機會

第7章 開發中產品的評估

  • 概要
  • 臨床實驗階段有潛力的疫苗
    • 季節性流感VLP (類病毒顆粒) 疫苗
    • VN-100
    • 四價季節性流感VLP疫苗
  • 臨床實驗的初期階段有潛力的疫苗
  • 全球主要國家以外開發中的其他疫苗

第8章 市場未來展望

  • 法國
    • 未來預測
    • 近幾年主要的事件
    • 推動及阻礙市場要素
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表一覽

目錄
Product Code: GDHC374CFR

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection's rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

A quadrivalent formulation of Intanza Intradermal is anticipated to be launched in the EU, following the launch of quadrivalent Fluzone Intradermal in the US. The sales of quadrivalent Intanza Intradermal are expected to increase to $1.5m in 2025. Its growth will be driven by its improved immunogenicity in elderly patients compared to typical influenza vaccines and the increase in the size of Germany's elderly population.

Scope

  • Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2015-2025.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU Seasonal Influenza Vaccines market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2015-2025 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Symptoms and Prognosis

4. Disease Management

  • 4.1. Seasonal Influenza Immunization Policy
    • 4.1.1. Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines
  • 4.2. France
    • 4.2.1. Influenza Immunization Recommendations and Policies
    • 4.2.2. Clinical Practice
  • 4.3. Germany
    • 4.3.1. Influenza Immunization Recommendations and Policies
    • 4.3.2. Clinical Practice
  • 4.4. Italy
    • 4.4.1. Influenza Immunization Recommendations and Policies
    • 4.4.2. Clinical Practice
  • 4.5. Spain
    • 4.5.1. Influenza Immunization Recommendations and Policies
    • 4.5.2. Clinical Practice
  • 4.6. UK
    • 4.6.1. Influenza Immunization Recommendations and Policies
    • 4.6.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands, Inactivated Vaccines
    • 5.2.1. Fluzone Quadrivalent
    • 5.2.2. Fluzone High-Dose
    • 5.2.3. Fluzone Intradermal
    • 5.2.4. Vaxigrip
    • 5.2.5. Fluarix Tetra
    • 5.2.6. Fluvirin
    • 5.2.7. Afluria
    • 5.2.8. Agrippal
  • 5.3. Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted)
    • 5.3.1. Fluad
  • 5.4. Product Profiles - Major Brands, Live-Attenuated Vaccines
    • 5.4.1. FluMist Quadrivalent
  • 5.5. Product Profiles - Major Brands, Cell Cultured Vaccines
    • 5.5.1. Flublok
    • 5.5.2. Flucelvax
  • 5.6. Other Seasonal Influenza Vaccines
    • 5.6.1. Influvac
    • 5.6.2. Minor Brands

6. Unmet Needs and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Higher Level of Public Awareness and Positive Perception of Influenza Vaccines
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Immunization Policies Targeting Children and Adolescents
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Enhanced Vaccine Efficacy in High-Risk Groups
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Vaccines Leveraging Innovative and Efficient Manufacturing Technologies
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improving the Cost-Effectiveness of Influenza Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Vaccines with Broader Influenza Strain Coverage
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Improved Vaccine Safety Profile
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Clinical Development
    • 7.2.1. Seasonal Influenza VLP Vaccine
    • 7.2.2. VN-100
    • 7.2.3. Quadrivalent Seasonal Influenza VLP Vaccine
  • 7.3. Promising Vaccines in Early-Stage Development
    • 7.3.1. FLU-v
    • 7.3.2. M-001
    • 7.3.3. TAK-850
    • 7.3.4. VAX-2012Q
  • 7.4. Other Vaccines in Development Outside the 7MM

8. Market Outlook

  • 8.1. France
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers
  • 8.2. Germany
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Italy
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Spain
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. United Kingdom
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccines Included
    • 9.4.3. Key Launch Dates
    • 9.4.4. Influenza Vaccine Tender System Assumptions
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Vaccine Assumptions
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Epidemiologists
    • 9.7.4. Director of Epidemiology
    • 9.7.5. Global Director of Therapy Analysis and Epidemiology
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Notable Influenza Pandemics
  • Table 2: Influenza Symptoms
  • Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016
  • Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016
  • Table 5: Country Profile - France
  • Table 6: Country Profile - Germany
  • Table 7: Country Profile - Italy
  • Table 8: Country Profile - Spain
  • Table 9: Country Profile - UK
  • Table 10: Leading Seasonal Influenza Vaccines, 2016
  • Table 11: Product Profile - Fluzone Quadrivalent
  • Table 12: Immunogenicity Profile of Fluzone Quadrivalent
  • Table 13: Local and Systemic AEs of Fluzone Quadrivalent
  • Table 14: Fluzone Quadrivalent SWOT Analysis, 2016
  • Table 15: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025
  • Table 16: Product Profile - Fluzone High-Dose
  • Table 17: Immunogenicity of Fluzone High-Dose Compared with Fluzone
  • Table 18: Local and Systemic AEs of Fluzone High-Dose
  • Table 19: Fluzone High-Dose SWOT Analysis, 2016
  • Table 20: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025
  • Table 21: Product Profile - Fluzone Intradermal
  • Table 22: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent
  • Table 23: Local andsystemic AEs of Fluzone Intradermal Quadrivalent
  • Table 24: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016
  • Table 25: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025
  • Table 26: Product Profile - Vaxigrip
  • Table 27: Cumulative Incidence of Influenza Infection in Children
  • Table 28: Local and Systemic AEs of Vaxigrip
  • Table 29: Vaxigrip SWOT Analysis, 2016
  • Table 30: Global Sales Forecast ($m) for Vaxigrip, 2015-2025
  • Table 31: Product Profile - Fluarix Tetra
  • Table 32: Immunogenicity Profile of Fluarix Tetra
  • Table 33: Local and Systemic AEs of Fluarix Tetra
  • Table 34: Fluarix Tetra SWOT Analysis, 2016
  • Table 35: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025
  • Table 36: Product Profile - Fluvirin
  • Table 37: Immunogenicity of Fluvirin in Adults
  • Table 38: Local and Systemic AEs of Fluvirin
  • Table 39: Fluvirin SWOT Analysis, 2016
  • Table 40: Global Sales Forecast ($m) for Fluvirin, 2015-2025
  • Table 41: Product Profile - Afluria
  • Table 42: Immunogenicity of Afluria in Adults
  • Table 43: Local and Systemic AEs of Afluria
  • Table 44: Afluria SWOT Analysis, 2016
  • Table 45: Global Sales Forecast ($m) for Afluria, 2015-2025
  • Table 46: Product Profile - Agrippal
  • Table 47: Immunogenicity of Agrippal
  • Table 48: Local and Systemic AEs of Agrippal
  • Table 49: Agrippal SWOT Analysis, 2016
  • Table 50: Global Sales Forecast ($m) for Agrippal, 2015-2025
  • Table 51: Product Profile - Fluad
  • Table 52: Immunogenicity Comparison of Fluad Versus Agriflu
  • Table 53: Local and Systemic AEs of Fluad
  • Table 54: Fluad SWOT Analysis, 2016
  • Table 55: Global Sales Forecast ($m) for Fluad, 2015-2025
  • Table 56: Product Profile - FluMist Quadrivalent
  • Table 57: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent
  • Table 58: AEs of FluMist Quadrivalent
  • Table 59: FluMist Quadrivalent SWOT Analysis, 2016
  • Table 60: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025
  • Table 61: Product Profile - Flublok
  • Table 62: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose
  • Table 63: Local and Systemic AEs of Flublok
  • Table 64: Flublok SWOT Analysis, 2016
  • Table 65: Global Sales Forecast ($m) for Flublok, 2015-2025
  • Table 66: Product Profile - Flucelvax
  • Table 67: Immunogenicity of Flucelvax
  • Table 68: Local and Systemic AEs of Flucelvax
  • Table 69:Flucelvax SWOT Analysis, 2016
  • Table 70: Global Sales Forecast ($m) for Flucelvax, 2015-2025
  • Table 71: Summary of Other Marketed Seasonal Influenza Vaccines, 2016
  • Table 72: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016
  • Table 73: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016
  • Table 74: Quadrivalent Versions of Marketed Vaccines
  • Table 75: Product Profile - Seasonal Influenza VLP Vaccine
  • Table 76: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
  • Table 77: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025
  • Table 78: Product Profile - VN-100
  • Table 79: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine
  • Table 80: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine
  • Table 81: VN-100 SWOT Analysis, 2016
  • Table 82: Global Sales Forecast ($m) for VN-100, 2015-2025
  • Table 83: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine
  • Table 84: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
  • Table 85: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025
  • Table 86: Promising Vaccines in Early-Stage Development, 2016
  • Table 87: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016
  • Table 88: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025
  • Table 89: Key Events Impacting Sales for Seasonal Influenza in France, 2015?2025
  • Table 90: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 91: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025
  • Table 92: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015?2025
  • Table 93: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 94: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025
  • Table 95: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015?2025
  • Table 96: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 97: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025
  • Table 98: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015?2025
  • Table 99: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 100: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025
  • Table 101: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015?2025
  • Table 102: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025
  • Table 103: Key Launch Dates
  • Table 104: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Influenza Virus Structure
  • Figure 2: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025
  • Figure 4: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025
  • Figure 5: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025
  • Figure 6: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025
  • Figure 7: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025
  • Figure 8: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025
Back to Top